Contact

Press Releases

Stay up to date on ReAlta’s news, scientific progress, clinical milestones, and mission to address severe inflammatory disease.
Press Release
Apr 08, 2026

ReAlta Life Sciences Closes Oversubscribed $40 Million Financing Round to Advance Pegtarazimod Phase 2 Program in Hypoxic Ischemic Encephalopathy (HIE)

Press Release
Jul 09, 2024
ReAlta Life Sciences Strengthens Board of Directors with Appointment of Accomplished Financial Executive